1 Investor Presentation NASDAQ:TNXP November 2020 Version P0256 11-16-20 (Doc 0733) © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Securi ...

1 Investor Presentation NASDAQ:TNXP P H A R M A C E U T I C A L S September 2020 Version P0246 9-3-20 (Doc 0699) © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as ...

1 Investor Presentation NASDAQ:TNXP P H A R M A C E U T I C A L S August 2020 Version P0244 8-17-20 (Doc 0695) © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION TONIX PHARMACEUTICALS HOLDING CORP. Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 (Exact name of registrant as specified in its charter) (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 26-1434750 (IRS Employer Identification No.) 509 Madison Avenue, Suite 1608 New York, New York 10022 (Addre ...

TNX-102 SL for Fibromyalgia - TNX-102 SL is in Phase 3 clinical development for Fibromyalgia, a chronic pain condition [6] - Interim analysis results for the Phase 3 RELIEF study are expected in the 3rd Quarter of 2020, with topline data expected in the 1st Half of 2021 [6] - A retrospective analysis of the AFFIRM study showed statistically significant improvement in mean pain using both MMRM (p < 0001) and MMRM with MI (p < 001) [36] - The new Phase 3 RELIEF study is enrolling with approximately 470 participants across 40 US sites [38] Pipeline Expansion - Tonix is exploring TNX-102 SL for Agitation in Alzheimer's Disease (AAD), with a proposed Phase 2 study that could potentially support NDA approval [47, 48] - TNX-102 SL is also being considered for Alcohol Use Disorder (AUD), with plans to submit an IND application in 1Q 2020 for a Phase 2 Proof of Concept Study [50, 51] - TNX-601 CR (Tianeptine Oxalate Controlled Release) is a potential daytime treatment for depression and PTSD, with plans to initiate a Phase 2 study in depression, ex-US, in the second half of 2020 [65, 70, 84] Other Programs - TNX-1300 (cocaine esterase) is in Phase 2 development for cocaine intoxication and has received FDA Breakthrough Therapy designation [7, 81] A Phase 2 study showed that TNX-1300 rapidly reversed the physiologic effects of cocaine, with cocaine plasma exposures dropping by 90% within two minutes [54] - TNX-801 (live horsepox virus) is a potential smallpox and monkeypox preventing vaccine in the pre-clinical stage [74, 82] - An estimated 6-12 million adults in the US have fibromyalgia [17]

Investor Presentation Biotech Showcase 2020 Version P0217 1-13-20 (Doc 0584) © 2020 Tonix Pharmaceuticals Holding Corp. 1 Cautionary Note on Forward-Looking Statements 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast ...

Investor Presentation December 2019 Version P0208 12-3-19 (Doc 0565) © 2019 Tonix Pharmaceuticals Holding Corp. 1 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estima ...